Steven Seedhouse
Stock Analyst at Cantor Fitzgerald
(3.33)
# 1,007
Out of 5,152 analysts
168
Total ratings
46.39%
Success rate
3.14%
Average return
Main Sectors:
Stocks Rated by Steven Seedhouse
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BCRX BioCryst Pharmaceuticals | Maintains: Overweight | $24 → $26 | $8.57 | +203.38% | 2 | Oct 15, 2025 | |
| DNTH Dianthus Therapeutics | Reiterates: Outperform | $56 → $63 | $62.02 | +1.59% | 4 | Sep 9, 2025 | |
| KRRO Korro Bio | Maintains: Strong Buy | $153 → $147 | $10.90 | +1,248.62% | 3 | Aug 13, 2025 | |
| MIRM Mirum Pharmaceuticals | Maintains: Strong Buy | $77 → $82 | $92.32 | -11.18% | 20 | Aug 7, 2025 | |
| WVE Wave Life Sciences | Initiates: Overweight | $10 | $13.95 | -28.32% | 3 | Apr 29, 2025 | |
| PHVS Pharvaris | Initiates: Overweight | $28 | $26.41 | +6.02% | 1 | Apr 29, 2025 | |
| IFRX InflaRx | Initiates: Overweight | $10 | $0.93 | +977.70% | 14 | Apr 29, 2025 | |
| VKTX Viking Therapeutics | Initiates: Overweight | $104 | $31.08 | +234.62% | 20 | Apr 28, 2025 | |
| QTTB Q32 Bio | Downgrades: Outperform | $90 → $22 | $4.66 | +372.10% | 2 | Dec 11, 2024 | |
| PRQR ProQR Therapeutics | Upgrades: Strong Buy | $6 → $14 | $1.65 | +748.48% | 6 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $93 | $145.12 | -35.92% | 9 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $57 → $68 | $39.24 | +73.29% | 3 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $67 → $106 | $20.65 | +413.32% | 15 | Jan 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $12 → $15 | $6.42 | +133.83% | 2 | Jan 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $27 → $56 | $14.91 | +275.59% | 4 | Jan 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $78 → $57 | $13.88 | +310.66% | 10 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $20 → $22 | $6.68 | +229.34% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $17 | $2.03 | +737.44% | 6 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $35 | $4.64 | +654.31% | 4 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $38 | $83.07 | -54.26% | 2 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $5 | $0.50 | +890.69% | 5 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $38 | $59.26 | -35.88% | 2 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $7.41 | - | 7 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $10.24 | - | 14 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.60 | - | 5 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $285 → $270 | $11.25 | +2,301.07% | 1 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $190.01 | - | 2 | Apr 23, 2020 |
BioCryst Pharmaceuticals
Oct 15, 2025
Maintains: Overweight
Price Target: $24 → $26
Current: $8.57
Upside: +203.38%
Dianthus Therapeutics
Sep 9, 2025
Reiterates: Outperform
Price Target: $56 → $63
Current: $62.02
Upside: +1.59%
Korro Bio
Aug 13, 2025
Maintains: Strong Buy
Price Target: $153 → $147
Current: $10.90
Upside: +1,248.62%
Mirum Pharmaceuticals
Aug 7, 2025
Maintains: Strong Buy
Price Target: $77 → $82
Current: $92.32
Upside: -11.18%
Wave Life Sciences
Apr 29, 2025
Initiates: Overweight
Price Target: $10
Current: $13.95
Upside: -28.32%
Pharvaris
Apr 29, 2025
Initiates: Overweight
Price Target: $28
Current: $26.41
Upside: +6.02%
InflaRx
Apr 29, 2025
Initiates: Overweight
Price Target: $10
Current: $0.93
Upside: +977.70%
Viking Therapeutics
Apr 28, 2025
Initiates: Overweight
Price Target: $104
Current: $31.08
Upside: +234.62%
Q32 Bio
Dec 11, 2024
Downgrades: Outperform
Price Target: $90 → $22
Current: $4.66
Upside: +372.10%
ProQR Therapeutics
Oct 29, 2024
Upgrades: Strong Buy
Price Target: $6 → $14
Current: $1.65
Upside: +748.48%
Jul 8, 2024
Upgrades: Outperform
Price Target: $93
Current: $145.12
Upside: -35.92%
May 10, 2024
Maintains: Strong Buy
Price Target: $57 → $68
Current: $39.24
Upside: +73.29%
Jan 11, 2024
Maintains: Strong Buy
Price Target: $67 → $106
Current: $20.65
Upside: +413.32%
Jan 9, 2024
Maintains: Strong Buy
Price Target: $12 → $15
Current: $6.42
Upside: +133.83%
Jan 4, 2024
Maintains: Strong Buy
Price Target: $27 → $56
Current: $14.91
Upside: +275.59%
Nov 10, 2023
Maintains: Outperform
Price Target: $78 → $57
Current: $13.88
Upside: +310.66%
Aug 15, 2023
Maintains: Strong Buy
Price Target: $20 → $22
Current: $6.68
Upside: +229.34%
Jun 13, 2023
Upgrades: Outperform
Price Target: $17
Current: $2.03
Upside: +737.44%
May 5, 2023
Maintains: Outperform
Price Target: $33 → $35
Current: $4.64
Upside: +654.31%
May 5, 2023
Upgrades: Outperform
Price Target: $38
Current: $83.07
Upside: -54.26%
Dec 7, 2022
Maintains: Outperform
Price Target: $15 → $5
Current: $0.50
Upside: +890.69%
Nov 9, 2022
Maintains: Outperform
Price Target: $30 → $38
Current: $59.26
Upside: -35.88%
Aug 10, 2022
Downgrades: Underperform
Price Target: n/a
Current: $7.41
Upside: -
Aug 5, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $10.24
Upside: -
May 18, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $0.60
Upside: -
Aug 6, 2021
Maintains: Outperform
Price Target: $285 → $270
Current: $11.25
Upside: +2,301.07%
Apr 23, 2020
Downgrades: Sell
Price Target: n/a
Current: $190.01
Upside: -